Table 2 Follow-up measures of medical consumption. Data are weighted for the sampling scheme.
None of the psychiatric disorder disorders | Anxiety or depressive disorder | Somatoform disorders, undifferentiated * | Somatoform disorder, others * | Total | |
|---|---|---|---|---|---|
Medical consumption | (n = 274) | (n = 51) | (n = 94) | (n = 12) | (n = 400) |
Data from patient records (1 yr): | |||||
Face-to-face contact with FP#: | |||||
mean (se) median | 4.8 (0.2) 4 | 7.5 (0.9) 7 | 6.9 (0.6) 5 | 9.8 (3.5) 5.5 | 5.5 (0.3) 4 |
Somatic prescriptions by FP&: | |||||
mean (se) median | 8.0 (0.6) 5 | 13.0 (3.6) 6 | 12.4 (1.7) 8 | 14.3 (4.2) 8.5 | 9.7 (0.7) 5 |
% use | 86% | 82% | 95% | 92% | 87% |
Antidepressants by FP&: | |||||
mean (se) median | 0.4 (0.1) 0 | 3.5 (1.0) 0 | 2.1 (0.4) 0 | 4.7 (2.1) 1 | 1.0 (0.2) 0 |
% use | 7% | 40% | 32% | 58% | 16% |
Psycholeptics by FP&: | |||||
mean (se) median | 0.6 (0.1) 0 | 4.2 (2.5) 0 | 2.3 (0.6) 0 | 4.9 (3.2) 0 | 1.5 (0.4) 0 |
% use | 20% | 37% | 46% | 25% | 27% |
Data from questionnaire (1/2 yr): | |||||
- contact with psychiatrist, psychologist or social worker | 14% | 59% | 39% | 68% | 23% |
- visit to hospital or specialist | 48% | 43% | 48% | 33% | 48% |
- admission to hospital | 7% | 14% | 10% | 0% | 8% |